Frequently Asked Questions

Yes — 100% free. All calculations run in your browser. No account, no payment, no data collection.

No data leaves your browser. Saved calculations use localStorage only. No server, no database, no tracking (unless you accept analytics cookies).

Yes — click the save button after calculating. Up to 20 calculations are stored in your browser's localStorage.

No. CalcMyPeptide provides educational calculation tools only. We do not sell, distribute, or recommend any peptide products.

Six tools: Reconstitution (vial mg + BAC water → units/mL), Blend/Stack (multi-peptide blends), Reverse (units drawn → dose received), GLP-1 Scheduler (weekly dose escalation timelines), Half-Life Visualizer (decay curves), and Vial Duration (how long a vial lasts at a given dose).

Yes, but sterile water has no preservative and is single-use only — use within 24 hours and discard remaining solution. Bacteriostatic water (0.9% benzyl alcohol) allows multi-dose use for up to 28 days.

21–28 days when reconstituted with bacteriostatic water and stored at 2–8°C (refrigerator). Lyophilized (freeze-dried) powder is stable for 12–24 months at room temperature when kept dry and away from light.

It depends on your desired concentration and syringe size. The most common approach: add 2 mL to a 5 mg vial to get 2.5 mg/mL (25 mcg per unit on a U-100 syringe). Use our Reverse Calculator to find the optimal volume for your setup.

No — always inject the bacteriostatic water slowly down the side of the vial to avoid denaturing the peptide. Never shake the vial; swirl gently until dissolved.

Lyophilized powder can generally be stored frozen for extended periods, but avoid freeze-thaw cycles once reconstituted. Reconstituted peptides should be refrigerated (2–8°C), not frozen.

A 0.3 mL (30-unit) insulin syringe is best for most peptide doses under 30 units due to finer graduation marks. For larger doses, use a 0.5 mL or 1.0 mL syringe. All U-100 insulin syringes share the same unit-to-mL ratio: 1 unit = 0.01 mL.

At a 5 mg/mL concentration, 0.25 mg = 5 units on a U-100 insulin syringe (0.05 mL). Use our Reconstitution Calculator for exact results at any concentration.

CJC-1295 with DAC has a half-life of 5.8–8.1 days, requiring only 1–2× weekly injections. Without DAC (Mod GRF 1-29), the half-life is ~30 minutes, requiring daily dosing — but when combined with a GHRP like Ipamorelin, it produces stronger pulsatile GH release.

After 5 half-lives, >97% of the peptide is eliminated from the body. Our Half-Life Visualizer shows this decay curve interactively for any peptide and dose.

Most research peptides are injected subcutaneously (SubQ) into the abdomen, 2+ inches from the navel, or into the outer thigh. Rotate sites with each injection to prevent lipodystrophy.

GLOW is a popular three-peptide regenerative stack combining GHK-Cu (copper peptide), BPC-157, and TB-500. It targets collagen production, wound healing, tissue repair, and skin/hair quality. GHK-Cu drives collagen and elastin synthesis; BPC-157 promotes angiogenesis and tendon repair; TB-500 accelerates cell migration and reduces inflammation.

KLOW is the GLOW stack with a fourth peptide added: KPV (Lysine-Proline-Valine), an anti-inflammatory alpha-MSH fragment. KPV inhibits NF-κB signaling to reduce systemic inflammation, allowing the repair peptides (BPC-157, TB-500) to work more effectively. KLOW is often described as "GLOW with immune control."

KLOW = GLOW + KPV. Both stacks use GHK-Cu, BPC-157, and TB-500. KLOW adds KPV for its systemic anti-inflammatory and immune-modulating properties. KLOW is preferred for chronic inflammatory conditions, autoimmune flares, or gut issues; GLOW is more focused on cosmetic and soft-tissue repair.

Typical blend protocol: Combine all peptides into a single vial with 2 mL bacteriostatic water. Standard research doses: GHK-Cu 1–2 mg/day; BPC-157 250 mcg/day; TB-500 2.5 mg 2× weekly. Use our Blend/Stack Calculator with the GLOW or KLOW preset to compute exact draw units.

Yes — all components are reconstituted into the same vial with bacteriostatic water. The calculator determines how many units to draw based on the target dose of the rate-limiting peptide (usually BPC-157). Use our Blend/Stack Calculator with the GLOW or KLOW quick-load preset.

Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist — it activates one receptor. Tirzepatide (Zepbound/Mounjaro) is a dual GIP + GLP-1 agonist, activating two receptors simultaneously for greater weight loss (up to 22.5% vs 15–17% for semaglutide at maximum approved doses). Both are FDA-approved for obesity.

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) in Phase III trials. Adding glucagon receptor activation increases energy expenditure. Phase III TRIUMPH-4 results (December 2025) showed 28.7% body weight loss at 12 mg over 68 weeks — significantly higher than tirzepatide's 22.5%.

Compounded semaglutide is manufactured by an FDA-registered 503B compounding pharmacy, typically at a lower cost than branded Wegovy/Ozempic. It uses the same active ingredient but is not FDA-reviewed for safety and efficacy. Availability depends on shortage status and state laws.

Units depend on your vial's concentration (mg/mL). At 5 mg/mL: 0.25 mg = 5 units, 0.5 mg = 10 units, 1.0 mg = 20 units. Use our GLP-1 Calculator — enter your compound concentration and it calculates exact units to draw each week of your escalation schedule.

A 5 mL vial at 5 mg/mL = 25 mg total. At the maintenance dose of 2.4 mg/week (semaglutide) that gives ~10 doses. Use our Vial Duration calculator for your exact dose and schedule.

BPC-157 upregulates VEGF and FGF to promote angiogenesis (new blood vessel formation), activates fibroblast migration for collagen repair, and protects the gut lining. It has demonstrated healing in tendons, ligaments, muscles, and GI tissue across multiple animal studies.

BPC-157 is localized and site-specific — best injected near the injury site or orally for gut issues. TB-500 (Thymosin Beta-4 fragment) is systemic — it promotes actin polymerization and cell migration throughout the body, making it effective for diffuse inflammation. Many researchers use them together for synergistic effects.

GHK-Cu stimulates collagen and elastin synthesis, promotes skin remodeling, and has anti-inflammatory and antioxidant effects. It also stimulates hair follicle cycling. It is one of the most well-researched cosmetic peptides with a strong safety profile.

Sermorelin is a GHRH analog that binds pituitary GHRH receptors to amplify GH pulse amplitude. Ipamorelin is a selective ghrelin receptor agonist that initiates GH pulse release without raising cortisol or prolactin. Used together, they produce 2–5× more GH than either alone.

Side effects vary by class. GLP-1 agents: nausea, diarrhea, constipation (especially during dose escalation). GH secretagogues: water retention, tingling at high doses, increased hunger (GHRP-6). BPC-157/TB-500: generally mild — occasional redness at injection site. GHK-Cu: minimal systemic effects.

Research peptides are not FDA-approved for human use, so clinical safety data is limited. The general safety profiles of BPC-157, TB-500, and GHK-Cu are considered favorable in animal studies. Always consult a qualified healthcare provider before using any research compound.

SubQ injections that accidentally go intramuscular are generally not dangerous — absorption may be faster. If a vein is accidentally hit, there is a higher risk of rapid systemic effects. For most research peptides this primarily means faster onset, but medical guidance is always advised.

In the United States, most research peptides exist in a legal gray area. They are legal to purchase for laboratory research purposes but not for human consumption. FDA-approved peptides (semaglutide, tirzepatide, PT-141, tesamorelin) can be obtained via prescription and compounding pharmacies. Laws vary by country.

A 503B outsourcing facility is an FDA-registered compounding pharmacy that produces sterile injectable medications at scale. They follow Current Good Manufacturing Practice (CGMP) and are subject to FDA oversight. Compounded GLP-1 agents from 503B facilities require a prescription.

Retatrutide (LY3437943) by Eli Lilly is in the Phase III TRIUMPH clinical program. FDA approval requires successful Phase III completion plus FDA review (typically 1–2 years). Based on TRIUMPH-4 data reported in December 2025, FDA submission is anticipated in 2026.